Aesica Pharmaceuticals announces the doubling of its development capacity—manufacturing multiple drug products up to phase 3 clinical trials at Queenborough. With the addition of the new capabilities, Aesica can now develop and manufacture a customer product from early formulation development through clinical manufacture and into commercialization—covering all aspects of product life cycle on the one…
API Manufacturing Trends
Aesica comments on API manufacturing trends. Aesica Pharmaceuticals sees the high levels of regulation—coupled with the continued evolution of the field, which has created challenges in the API manufacturing industry—as being a great opportunity to exhibit high quality and regulatory compliance best practice, and to continually increase confidence within the marketplace. “Competition with low cost…